Imatinib carbaldehyde

Target: This ligand targets ABL1, KIT, and PDGFR tyrosine kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for ABL1, KIT, and PDGFR tyrosine kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings ABL1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC E3 Ligase Recruitment: Imatinib carbaldehyde can be used as a warhead in PROTAC designs to engage the target kinase while enabling recruitment of an E3 ubiquitin ligase. This approach supports ubiquitination and proteasome-mediated degradation, allowing researchers to probe whether catalytic inhibition or degradation yields stronger pathway suppression in kinase-driven models.

• Kinase Degradation Studies: As a kinase-binding ligand, Imatinib carbaldehyde is suitable for constructing PROTACs aimed at degrading specific imatinib-sensitive kinases. Researchers can evaluate degradation kinetics, dose–response relationships, and dependence on ubiquitin–proteasome activity to distinguish degrader-specific effects from occupancy-driven inhibition.

• Resistance Mechanism Probing: PROTACs incorporating Imatinib carbaldehyde can be applied to investigate how targeted degradation performs under resistance-associated alterations. By comparing degradation and signaling outcomes across mutant or bypass contexts, experiments can clarify whether degraders overcome impaired binding, altered conformations, or compensatory pathway activation.

• Target Pathway Modulation: Imatinib carbaldehyde-based PROTACs can be used to modulate downstream signaling by removing the kinase protein rather than only blocking its activity. This enables mechanistic studies of pathway rewiring, identification of degradation biomarkers, and assessment of phenotypic changes linked to sustained protein loss.

Imatinib carbaldehyde is a ABL/Src-family kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Imatinib carbaldehyde is characterized by aldehyde/oxime-compatible carbonyl functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The aldehyde or oxime-related handle is compatible with oxime, hydrazone, reductive amination, or secondary functionalization strategies for linker introduction. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.